Medivir AB, a pharmaceutical company focused on developing treatments for cancer in areas of high unmet medical need, has selected a global CRO partner for the planned phase 2b study evaluating fostroxacitabine bralpamide (fostrox) + Lenvima vs Lenvima alone in second line HCC.   In the next phase of development, Medivir is planning for a global, randomized phase 2b study aligned with its recent supportive Type C interaction with the FDA. The objective is to evaluate the combination of fostrox...